Life Science Leader is an essential business publication for life science executives who work at everything from emerging biotechs to large pharmaceutical companies. Our content is designed to inform ...
Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing ...
With the exciting promise of addressing previously unmet medical needs, the rapidly growing field of gene therapy has already begun to revolutionize patient treatment. The ability to create a genetic ...
CEO Corner articles are written by presidents or CEOs of biopharmaceutical or medical device companies that create a drug or device. These articles discuss global industry trends, experiences, and ...
The FDA designates an outsourcing facility that produces sterile injectable medication as well as other sterile medical products as a 503(b) compounder. Working with 503(b) compounding facilities ...